Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 5, 2004

View Archived Issues

First patient enrolled in trial of dendritic cell vaccine for melanoma

Extended phase I trial of INT for diabetes

CTX granted for phase IIa trial of ATL-104 for mucositis

Positive proof of concept results for SUDCA

Chiron licenses Coley's VaxImmune

Strategic alliance and IND plans for new DNA-based HIV vaccine

Dynogen to develop Mitsubishi neurological compound for IBS

Novartis files sNDA for new indication for Diovan

Wex files CTA for pivotal Tectin trial

Methylphenidate improves fatigue and physical well being in advanced cancer patients

PGN-0052 advances to phase II

IL-18 vaccination as a potential strategy for treating lupus

HEP DART 2003 meeting highlights: Phase Ib data presented for isatoribine

Merimepodib enhances the anti-HCV activity of PEG-IFN and ribavirin

DMC recommends continuation of phase III Oncophage trial

Cardiome submits oxypurinol NDA

ICA-69673 set to enter phase I

Nastech submits abbreviated NDA for Calcitonin-Salmon nasal spray

Preclinical milestone achieved in Neurogen/Aventis collaboration

Abbott and Protein Design Labs enter IL-12 licensing agreement

Novel anti-Helicobacter pylori agents developed by Shionogi researchers

New anti-herpes virus compounds reported by Yamanouchi and Rational Drug Design

Banyu team reports the preparation and use of new ORL1 antagonists

Bislactone-based acetyl-CoA carboxylase inhibitors newly identified at Ajinomoto

New 5-HT6 modulators, their preparation and use described in Roche patent

Insight into the mechanism of the antilipemic effects of FR-218944

Improved profile of TRA-418 possibly due to dual activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...